Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Files An 8-K Regulation FD Disclosure

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

Story continues below

The Company is currently exploring a potential refinancing of its 540 acre Sawston UK property in view of a major new lease and actual and planned further improvements to the property. In the exploration of more favorable financing terms with mortgage lenders, one party has requested that we make public the most recent letter update of the appraisal of the property provided to us for our evaluations. With the concurrence of the appraiser, the most recent such appraisal letter is attached hereto as Exhibit 99.1.

The Company is accommodating this request in this instance and does not undertake any duty to provide further updates. The attached letter contains forward-looking information in the form of assumptions, estimates, and appraisals. As with any forward-looking information, actual outcomes could differ. For example, the economy and the real estate market in the UK, as well as the exchange rate between the British Pound Sterling and the U.S. Dollar, could fluctuate in a manner that is difficult to anticipate.

The information contained in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits.
Exhibit No. Description
99.1 Appraisal Letter, dated December 19, 2017.


NORTHWEST BIOTHERAPEUTICS INC Exhibit
EX-99.1 2 tv489110_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1       19th December 2017 T +44 (0)20 7198 2000   F +44 (0)20 7198 2001 Private & Confidential www.lsh.co.uk   Lambert Smith Hampton Dennis Mehiel Esq United Kingdom House Four M Purchasers LLC 180 Oxford Street 7 Renaissance Square,…
To view the full exhibit click here

About Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company’s lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company’s platform technology, DCVax, uses activated dendritic cells to mobilize a patient’s own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.

An ad to help with our costs